[1]吴 楠,孙立如,李亚东,等.非肌层浸润性膀胱癌组织中OTUD5 和RNF186 表达与临床病理特征的关系及预后价值研究[J].现代检验医学杂志,2024,39(05):75-79+101.[doi:10.3969/j.issn.1671-7414.2024.05.014]
　WU Nan,SUN Liru,LI Yadong,et al.Study on the Clinicopathological Characteristics and Prognostic Value of the Expression of OTUD5 and RNF186 in Non-muscle Invasive Bladder Cancer[J].Journal of Modern Laboratory Medicine,2024,39(05):75-79+101.[doi:10.3969/j.issn.1671-7414.2024.05.014]
点击复制

非肌层浸润性膀胱癌组织中OTUD5 和RNF186 表达与临床病理特征的关系及预后价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年05期
页码:
75-79+101
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Study on the Clinicopathological Characteristics and Prognostic Value of the Expression of OTUD5 and RNF186 in Non-muscle Invasive Bladder Cancer
文章编号:
1671-7414（2024）05-075-06
作者:
吴 楠1; 孙立如1; 李亚东1; 刘文军2
（1. 唐山市中医院泌尿外科，河北唐山063000；2. 迁安市人民医院泌尿外科，河北唐山 064400）
Author(s):
WU Nan1;  SUN Liru1;  LI Yadong1;  LIU Wenjun2
（1. Department of Urology, Tangshan Traditional Chinese Medicine Hospital, Hebei Tangshan 063000, China； 2. Department of Urology, Qian’an People’s Hospital, Hebei Tangshan 064400，China）
关键词:
非肌层浸润膀胱癌; 结构域蛋白去泛素化酶5; 环指蛋白186; 临床病理特征
分类号:
R737.14；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.05.014
文献标志码:
A
摘要:
目的 研究非肌层浸润膀胱癌（non-muscle invasive bladder cancer，NMIBC）癌组织中结构域蛋白去泛素化酶5（domain protein ubiquitin 5，OTUD5）、环指蛋白186（ring finger protein 186，RNF186）表达与临床病理特征的关系及预后价值研究。方法 收集2019 年1 月～ 2020 年1 月唐山市中医院收治的106 例NMIBC 患者。免疫组织化学检测NMIBC 癌组织及癌旁组织OTUD5，RNF186 表达。比较不同临床病理特征NMIBC 癌组织OTUD5，RNF186 表达差异。Kaplan-Meier 曲线分析（Log-Rank 检验）OTUD5，RNF186 表达对NMIBC 无进展生存预后的影响。COX 回归模型分析影响NMIBC 患者无进展生存预后的因素。结果 NMIBC 癌组织中OTUD5（62.26%），RNF186（66.04%）的阳性率高于癌旁组织（11.32%，8.49%），差异具有统计学意义（χ2=59.146，75.079，均P ＜ 0.05）。NMIBC 癌组织中OTUD5 与RNF186 表达呈显著正相关（r=0.659，P ＜ 0.05）。T 1 期、高级别尿路上皮癌NMIBC 癌组织中OTUD5（72.97%， 84.21%），RNF186（77.03，86.84%）阳性率高于Ta/Tis 期（37.50%，50.00%）、低级别尿路上皮癌（40.63%，54.41%）， 差异具有统计学意义(χ2=11.964，13.199；12.143，11.431， 均P ＜ 0.05）。OTUD5 阳性组(40.91%)、RNF186 阳性组(45.71%) 三年累积无进展生存率低于OTUD5 阴性组(90.00%)、RNF186 阴性组(86.11%) 患者（Log-Ranktest χ2=24.710，14.586，均P ＜ 0.05）。OTUD5 阳性（OR=1.446，95%CI：1.086 ～ 1.925）、RNF186 阳性（OR=1.579，95%CI：1.132 ～ 2.024）、肿瘤TNM 分期T1 期(OR=1.582,95%CI:1.219~2.054)、病理分级高级别（OR=1.570，95%CI：1.188 ～ 2.074）是影响NMIBC 患者无进展生存的独立危险因素( 均P ＜ 0.001）。结论 NMIBC 患者癌组织OTUD5，RNF186 表达升高，与肿瘤TNM 分期、病理分级有关，是影响NMIBC 患者预后的独立危险因素。
Abstract:
Objective To study the expression of domain protein ubiquitin 5 (OTUD5) and ring finger protein 186 (RNF186) in non-muscle invasive bladder cancer (NMIBC) and their relationship with clinicopathological characteristics and prognostic value. Methods A total of 106 NMIBC patients admitted to Tangshan Traditional Chinese Medicine Hospital from January 2019 to January 2020 were collected. OTUD5 and RNF186 expression in NMIBC cancer tissue and para-cancer tissue were detected by immunochemistry. The differences between OTUD5 and RNF186 expressions in NMIBC cancer tissues with different clinical and pathological characteristics were compared. Kaplan-Meier curve analysis (Log Rank test) was used to analyze the impact of OTUD5 and RNF186 expression on progression free survival of NMIBC. COX regression model analysis was used to analyze factors affecting progression free survival in NMIBC patients. Results The positive rates of OTUD5 (62.26%) and RNF186 (66.04%) in NMIBC cancer tissue were higher than those in adjacent tissues（11.32%，8.49%）, with significant differences (χ2=59.146, 75.079, all P<0.05). There was a significant positive correlation between OTUD5 and RNF186 expressions in NMIBC cancer (r=0.659, P<0.05). The positive rates of OTUD5 (72.97% ，84.21%) and RNF186 (77.03%, 86.84%) in T1 stage and high-grade NMIBC cancer tissues were higher than those in Ta/Tis stage（37.50%，50.00%）and low-grade cancer tissues(40.63%，54.41%), and the differences were significant (χ2=11.964，13.199；12.143，11.431，all P<0.05). The 3-year cumulative progression free survival rate of patients in the OTUD5 positive group (40.91%)and RNF186 positive group(45.70%) were lower than that in the OTUD5 negative group(90.00%) and RNF186 negative group (86.11%) (Log Rank test χ2=24.710, 14.586, all P<0.05). OTUD5 positive (OR=1.446，95%CI：1.086 ～ 1.925), RNF186 positive (OR=1.579，95%CI：1.132 ～ 2.024), Tumor TNM stage T1 (OR=1.582，95%CI：1.219~2.054) and high pathological grade (OR=1.570，95%CI：1.188~2.074） were independent risk factors affecting progression free survival in NMIBC patients（all P<0.001）. Conclusion The increased expression of OTUD5 and RNF186 in cancer tissue of NMIBC patients are related to tumor TNM staging and pathological grading and are independent risk factors affecting the prognosis of NMIBC patients.

参考文献/References:

[1] LOBO N, AFFERI L, MOSCHINI M, et al. Epidemiology, screening, and prevention of bladder cancer[J]. European Urology Oncology, 2022, 5(6):628-639.
[2] 邢俊杰, 盛永亮, 张浩然, 等. 非肌层浸润性膀胱癌TURBT 治疗患者血清UBC1 和DJ-1 表达水平及其对预后预测价值研究[J]. 现代检验医学杂志, 2023,38(3): 29-34. XING Junjie, SHENG Yongliang, ZHANG Haoran, et al. Study on serum UBC1, DJ-1 expression levels and their prognostic value in patients with non muscular invasive bladder cancer treated with TURBT[J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 29-34.
[3] CHO J H, KIM K, KIM S A, et al. Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways[J]. Cell Death and Differentiation, 2021, 28(3): 900-914.
[4] LI Xuebing, LU Baohua, ZHANG Lina, et al. Mechanism of OTUD5 in non-small cell lung cancer cell proliferation, invasion, and migration[J]. Bosnian Journal of Basic Medical Sciences, 2022, 22(6): 901- 911.
[5] BAI Mixue, CHE Yingying, LU Kun, et al. Analysis of deubiquitinase OTUD5 as a biomarker and therapeutic target for cervical cancer by bioinformatic analysis[J]. PeerJ, 2020, 8: e9146.
[6] ZHANG Huazhi, CUI Zhihui, CHENG Du, et al. RNF186 regulates EFNB1(ephrin B1)-EPHB2- induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis[J]. Autophagy, 2021, 17(10): 3030-3047.
[7] OKAMOTO T, IMAIZUMI K, KANEKO M. The role of Tissue-Specific ubiquitin ligases, RNF183, RNF186, RNF182 and RNF152, in disease and biological function[ J]. International Journal of Molecular Sciences, 2020, 21(11): 3921.
[8] ?LVAREZ-MAESTRO M, GUERRERO-RAMOS F, RODR?GUEZ-FABA O, et al. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)[J]. Actas Urologicas Espanolas, 2021, 45(2): 93-102.
[9] SOUKUP V, ?APOUN O, COHEN D, et al. Risk stratification tools and prognostic models in nonmuscle- invasive bladder cancer: a critical assessment from the European association of urology non-muscleinvasive bladder cancer guidelines panel[J]. European Urology Focus, 2020, 6(3): 479-489.
[10] CRUZ WALMA D A, CHEN Zhuoyao, BULLOCK A N, et al. Ubiquitin ligases: guardians of mammalian development[J]. Nature Reviews Molecular Cell Biology, 2022, 23(5): 350-367.
[11] KANG Xiaoyun, ZHANG Jing, TANG Ling, et al. OTU deubiquitinase 5 inhibits the progression of non-small cell lung cancer via regulating p53 and PDCD5[J]. Chemical Biology & Drug Design, 2020, 96(2): 790-800.
[12] GUO Xirui, HUANG Haishan, JIN Honglei, et al. ISO, via upregulating miR-137 transcription, inhibits GSK3β-HSP70-MMP-2 axis, resulting in attenuating urothelial cancer invasion[J]. Molecular Therapy. Nucleic Acids, 2018, 12: 337-349.
[13] HOU Tao, DAN Weichao, LIU Tianjie, et al. Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression[J]. Cell Death & Disease, 2022, 13(9): 778.
[14] ZHANG Yujiao, FAN Yizeng, JING Xin, et al. OTUD5- mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triplenegative breast cancer progression[J]. Cancer Letters,2021, 504: 104-115.
[15] RANJAN K, HEDL M, SINHA S, et al. Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response[J]. Journal of Clinical investigation, 2021, 131(17):e145472.
[16] HU Xiuqi, ZHANG Qifan, GUO Manyu, et al. Deletion of RNF186 expression suppresses diet-induced hepatic steatosis by regulating insulin activity[J]. iScience, 2022, 25(2): 103859.
[17] JI Yizhong, TU Xucan, HU Xiuqi, et al. The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-κB[J]. Cellular Signalling, 2020, 75: 109764.
[18] ZHANG Huazhi, CUI Zhihui, PAN Ting, et al. RNF186/EPHB2 axis is essential in regulating TNF signaling for colorectal tumorigenesis in colorectal epithelial cells[J]. Journal of Immunology, 2022, 209(9): 1796-1805.
[19] CHAN Junwei, NEO C W Y, GHOSH S, et al. HNF1A binds and regulates the expression of SLC51B to facilitate the uptake of estrone sulfate in human renal proximal tubule epithelial cells[J]. Cell Death & Disease, 2023, 14(5): 302.
[20] WANG Xueyao, HU Rui, SONG Zhenwei, et al. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STINGmediated anti-tumor immunity[J]. Cancer Letters, 2022,547: 215880.

相似文献/References:

[1]朱军,沈欣,曹冬.非肌层浸润性膀胱癌组织中PKM2 和ALYREF 表达及与预后预测价值研究[J].现代检验医学杂志,2023,38(05):110.[doi:10.3969/j.issn.1671-7414.2023.05.021]
　ZHU Jun,SHEN Xin,CAO Dong.Expression of PKM2 and ALYREF in Non-muscular Invasive Bladder Cancer and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(05):110.[doi:10.3969/j.issn.1671-7414.2023.05.021]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题（编号：20201442）。
作者简介：吴楠（1977-），男，本科，副主任医师，研究方向：泌尿系统肿瘤诊治，E-mail：wunan200807@163.com。
更新日期/Last Update: 2024-09-15